### Index

A1c test. *See* Hemoglobin A1c

A. *actinomycetemcomitans*-induced periodontitis, 131–32

Acarbose, 40
side effects of, 41

ACOG. *See* American College of Obstetricians and Gynecologists

Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE), 144

Acute dental problems, managing, 106

ADA. *See* American Diabetes Association

Addison’s disease, 60

Adolescents. *See also* Children
dental caries in, 159
periodontal health and diabetes in, 126
Adult-onset diabetes. *See* Type 2 diabetes

ADVANCE. *See* Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation

Advanced glycation end products (AGEs), 130–31

Age, 29
diabetes and, 31, 33
incidence of diabetes by, 29f
type 2 diabetes and, 9
AGEs. *See* Advanced glycation end products

Alcoholism, chronic, 173–74

American College of Obstetricians and Gynecologists (ACOG), 35

OGTT criteria, 37

American Diabetes Association (ADA), 3

American Indians, prediabetes prevalence in, 31

Amylin, 79

Angular cheilitis, 167–68, 170f

Antibiotics, 13

Antimicrobial photodynamic therapy (aPDT), 150

Antiplatelet agents for CHD, 58

aPDT. *See* Antimicrobial photodynamic therapy

Atorvastatin, 229

Autoimmune disease associated with diabetes, 60

Autoimmune thyroid disease, 60

Autoimmunity, type 1 diabetes and, 5–6

Autonomic neuropathy, 53
cardiac, 54
gastrointestinal, 54
genitourinary, 54

Bacteria, oral/periodontal, 152

Bacteroidetes, 6–7, 13

Bariatric surgery, 40

Basal insulin, 75
for type 1 diabetes, 76–77

Benign parotid hypertrophy, 172–74, 173f, 174f

β cell destruction, type 1 diabetes and, 5, 28
function, in type 2 diabetes, 10, 28

---

Biologic mechanisms
adverse effects of diabetes on periodontal health and, 127–32
AGEs, 130–31
altered host inflammatory response, 128–30
altered subgingival microflora, 127–28
bone resorption and bone formation uncoupling, 131–32
Blood glucose, elevated, 37
Blood glucose meters, 219f
Blood glucose testing, 197–98, 198f
Blood pressure control
CHD and, 56–57
nephropathy and, 53
BMS. See Burning mouth syndrome
Bolus insulin, 75
for type 1 diabetes, 77–78
Bone disease associated with diabetes, 62–63
Bone loss, periodontal, 131, 132f
Burning mouth syndrome (BMS), xiii, 168–72
Candida infection and, 170–72
chronic kidney disease and, 172
disorders associated with, 170
neuropathy and, 170–71
Calorie restriction for type 2 diabetes, 242
Cancer, 62
pancreatic, 20
Candida albicans, 47–48
in oral cavity, 164
Candida infection
BMS and, 170–72
clinical appearance of, 165–68, 166f, 167f, 168f, 169f, 170f
dentures and, 164–65, 166f
insulin and, 163–64
non-albicans species of, 164
Candidiasis, xiii
xerostomia and, 226
Cardiomyopathy in diabetes, 59
Cardiovascular disease (CVD), 55
periodontal disease and, 144
Caries
coronal, 157–58
dental, 157–60
root, 157–58, 160f
Carpenter and Coustan plasma glucose criteria, 36
CD. See Celiac disease
CDEs. See Certified diabetes educators
Celiac disease (CD), 60
Cerebrovascular disease, 59
Certified diabetes educators (CDEs), 69
CGM. See Continuous glucose monitoring
CHD. See Coronary heart disease
Children
dental caries in, 159
diabetes in, 33
obesity in, 29
periodontal health and diabetes in, 126
Chronic kidney disease, BMS and, 172
Classification of diabetes, 27–33
MODY, 30–31
type 1 diabetes, 28
type 2 diabetes, 28
Clinical Laboratory Improvement Amendments (CLIA), 116
Conditions associated with diabetes, 60t
autoimmune disease, 60
bone disease, 62–63
cancer, 62
fatty liver disease, 61
hearing impairment, 63
intraoral, 245
mental illness, 62
musculoskeletal complications, 62
OSA, 61
sexual dysfunction, 61–62
skin diseases, 63, 64f
Continuous glucose monitoring (CGM), 70
Continuous subcutaneous insulin infusion (CSII), 73
disadvantages of, 78–79
pump and associated equipment, 207f, 208
for type 1 diabetes, 78–79
Coronal caries, 157–58
Coronary heart disease (CHD), 55–56
antiplatelet agents for, 58
blood pressure control and, 56–57
dyslipidemia and, 57
glycemic control and, 56
management of, 58, 58t
smoking and, 57
C peptide, 30
CSII. See Continuous subcutaneous insulin infusion
CVD. See Cardiovascular disease

Cytokine stimulation in human islets, 5

Dental appointments, timing of, 116–17

Dental care
  access to, 181–82
  hypoglycemic event during, case study of, 215–20
  for medically complex patients, xiv
  type 1 diabetes, case study of, 205–8

Dental caries, 157–60
  in children/adolescents, 159
  hyperglycemia and, 158
  metabolic control and, 159
  type 1 diabetes and, 159
  type 2 diabetes and, 158–59
  xerostomia and, 226

Dental implants
  complications of, 178
  diabetes mellitus and, 175–81
    animal models of, 176–78
    clinical studies of, 178–81
  done-to-implant contact, 176–77
  failure of, 101, 178–79
  healing of, 176–77, 180
  outcomes of, 177–78, 180
  placement of, 245
  success rates of, 179
  therapy, 109–10
    glycemic control and, 101
    results of, 101

Dental office, management of diabetes mellitus in
  dental appointment timing and, 116–17
  dental implant therapy results, 101
  diabetes emergency evaluation and management in, 110–16
  glycemic control and, 105–6
  hypoglycemia in, 111–16
  oral evaluation and, 102
  pain management and, 117–18
  pathways of care for
    diagnosis diabetes and, 104–6, 105f
    treatment plan and therapy, 106–18, 107f
    undiagnosed diabetes and, 101–4, 103f
    periodontal therapy results, 99–101

Dental patients
  diabetes identification in dental settings, 192–95, 195t
  diabetes testing in dental settings and, 196–99
  medical conditions screening and, 197
  with undiagnosed diabetes, 191–200, 195t

Dental risk factors, 102

Dental settings
  blood glucose testing in, 197–98, 198f
  diabetes identification in, 192–95, 195t, 200t
  diabetes testing in, 196–99
  prediabetes detection in, 200t
  primary health care activities in, 196
  screening in, 197

Dental treatment for patients with diabetes, 109–10

Dentist
  communication with physician, 104
  diabetes management and, 203
  glycemic control determination and, 107–8
  questions for, 203–4
  dental office screening by, 197
  primary health care activities and attitudes of, 196

Dentures
  Candida infection and, 164–65, 166f
  stomatitis, 165, 165f

Diabetes. See also Type 1 diabetes; Type 2 diabetes
  causes of, 20, 27–28
  epidemiology of, 31–33
  incidence of, 27, 29f
  prevalence, 27
  prevention of, 21

Diabetes mellitus
  nomenclature for, 27
  periodontal health and adverse effects of, 122–27, 123t, 124t, 125t
    biologic mechanisms contributing to, 127–32
  Diabetes Prevention Program (DPP), 39, 88–89, 234
    trial, 21

Diabetic foot, 54–55

Diabetic ketoacidosis (DKA), 45–46, 46t, 110–11
Diagnosis of diabetes, 33t
in dental office, 104–6
fasting plasma glucose and, 34
GDM, 17, 35–37, 36t
glucose concentrations and, 30
HbA1c and, 33
MODY, 20
prosthodontic rehabilitation and, case study of, 229–35, 230f, 231f, 232f
two-hour plasma glucose and, 34
Diagnostic criteria for diabetes mellitus, 33,
33t, 242t
DIAGRAM consortium, 11
Dipeptidyl peptidase-4 (DPP-4) inhibitors, 83–84
Distal symmetric polyneuropathy (DSPN), 53–54
DKA. See Diabetic ketoacidosis
“Double diabetes,” 8
DPP. See Diabetes Prevention Program
DPP-4 inhibitors. See Dipeptidyl peptidase-4 inhibitors
Dry mouth, 161
DSPN. See Distal symmetric polyneuropathy
Dyslipidemia, CHD and, 57
eAG. See Estimated average glucose
ED. See Erectile dysfunction
Edema, macular, 50–51
Elevated blood glucose, 37
Emergencies
diabetes, dental office evaluation and management of, 110–16
hyperglycemic, 46t, 110–11
Emphysematous cholecystitis, 48
End-stage renal disease (ESRD)
nephropathy and, 52
periodontitis and, 144
Environment
risk factors and, 38
type 1 diabetes and, 6
Environmental pollution, type 2 diabetes and, 15
Epidemiology of diabetes, 31–33
Erectile dysfunction (ED), 61
ESRD. See End-stage renal disease
Estimated average glucose (eAG), 108
HbA1c and, 109
Eye exams, 51
Fasting plasma glucose (FPG), 3
diabetes diagnosis and, 34
prediabetes and, 35
Fatty liver disease, 61
Firmicutes, 13
Foot, diabetic, 54–55
FPG. See Fasting plasma glucose
Fractures, HbA1c and, 101
Framingham risk score, 196
“Fruity” breath odor, 111
GAD65, 4
Gastrointestinal infections, 47–48
GCF. See Gingival crevicular fluid
GDM. See Gestational diabetes
Genetics
risk factors and, 38
of type 1 diabetes, 4–5
non-HLA loci associated with, 4–5, 5t
of type 2 diabetes, 10–11, 15–16
Genitourinary infections, 47
Genome wide association studies (GWAS)
in type 1 diabetes, 4–5
in type 2 diabetes, 11
Gestational diabetes (GDM)
definition of, 17
diagnosis of, 17, 35–37, 36t
glucose concentrations and, 30
epidemiology of, 17
etiology of, 17–18
hyperglycemia in, 17
inflammatory markers and, 18
insulin resistance and, 18
metabolic factors in, 17–18
obesity and, 17
OGTT for, 36
periodontal health and, 126–27
prevalence of, 33
prevention of, 40
risk factors for, 37–38
risk factors for, 37–38
type 2 diabetes and, 9–10
vitamin D and, 18–19
GFR. See Glomerular filtration rate
Gingival crevicular blood, 194–95
Gingival crevicular fluid (GCF), 162
Gingivitis, 102, 121
prevalence of, 122
Glimepiride, 215
Glomerular filtration rate (GFR), 52
GLP-1. See Glucagon-like peptide-1
GLP-1 receptor agonists, 233
for type 2 diabetes, 83
Glucagon, hypoglycemia and, 86, 116
Glucagon-like peptide-1 (GLP-1), 79
Glucokinase, MODY and, 20
Glucometers, 39
in dental office, 116
glycemic control determination with, 107
hypoglycemia and readings on, 114–15
Glucose concentrations
GDM diagnosis and, 30
high-risk, 35
Glucose dysregulation, obesity and, 134
Glucose levels
dental appointment timing and, 117
HbA1c values and, 108–9, 109t
medications and raise in, 86–87
Glucose monitoring
CGM, 70
home, 75
SMBG, 70
Glucose regulation, GDM and, 30
α-Glucosidase inhibitors for type 2 diabetes, 84
Glyburide, 210
Glycemic control
assessments of, 70–71, 71t
CHD and, 56
determining dental patient’s, 106–8, 107f
diabetes management in dental office and, 105–6
diabetes type and, 105–6
glucose levels and values of, 108–9, 109t
hypoglycemia and values of, 113–14
periodontal therapy and changes in, 147, 150
retinopathy and, 34–35, 34f
type 1 diabetes and values of, 108–9
type 2 diabetes and values of, 108–9
Hepatitis B (HBV), 48
Hepatitis C (HCV), 48
HHS. See Hyperglycemic hyperosmolar state
HIV. See Human immunodeficiency virus
HLA. See Human leukocyte antigen
HNF1α, MODY and, 20
Home glucose monitoring, 75
Host inflammatory response
altered, 128–30
type 1 diabetes and, 128–29
type 2 diabetes and, 128–29
Human immunodeficiency virus (HIV), 49
Human leukocyte antigen (HLA), 4
Hydrochlorothiazide, 229
Hyperglycemia, 3, 33–34
  approach to management of, 72f
  chronic complications caused by, 50
  dental caries and, 158
  epigenetic changes and, 49–50
  in GDM, 17
  symptoms of, 218f
  treatment of, 220
  undiagnosed, 195
Hyperglycemic crisis, 33–34
Hyperglycemic emergencies, 46t, 110–11
Hyperglycemic hyperosmolar state (HHS), 46, 46t
Hyperventilation, 111
Hypoglycemia, 46, 85–86
  in dental office, 111–16
  glucagon for, 86, 116
  glucometer readings and, 114–15
  glycemic control and, 114
  HbA1c values and, 113–14
  insulin therapy and, 111–12, 112t
  neurologic impairment and, 112–13
  oral diabetes medications associated with, 113, 113t
  oral medications associated with, 210, 211t
  prevention of, 114
  signs of, 112t
  symptoms of, 86, 112t, 217f
  treatment of, 86, 112t, 219–20
Hypoglycemia unawareness, 114
Hypoglycemic events
  during dental care, case study of, 215–20
  intraoperative, 115
Hypotension, 111
Hypothermia, 111
IA-2, 4
IA-2β, 4
IADPSG. See International Association of the Diabetes and Pregnancy Study Groups
IDDM. See Insulin-dependent diabetes mellitus
IFG. See Impaired fasting glucose
IGT. See Impaired glucose tolerance
IL2RA, 4
Impaired fasting glucose (IFG), 35
Impaired glucose tolerance (IGT), 35
Impaired wound healing, 132–33
Incidence of diabetes, 27, 29f
Infections, 46–47
  Candida, 163–68
  gastrointestinal, 47–48
  genitourinary, 47
  head and neck, 48
  liver, 47–48
  periodontal, 150–51
  respiratory, 47
  skin and soft tissue, 48–49
  surgical site, 49
Infectious agents, type 1 diabetes and, 6
Inflammation
  diabetes and, 150
  periodontal therapy and, 151–52
Inflammatory markers, GDM and, 18
Inflammatory mediators in saliva, 162
Inflammatory response, host, 128–30
Insulin, 206t
  basal, 75
    for type 1 diabetes, 76–77
  bolus, 75
    for type 1 diabetes, 77–78
  Candida and, 163–64
  deficiency
    DKA and, 111
    of type 1 diabetes, 28
    injections, 75–76, 76f
    Levemir, 215
    measuring, 30
    prandial, 75
    preparations of, 76t
    for type 2 diabetes, 30, 84–85
Insulin-dependent diabetes mellitus (IDDM), 27
Insulin detemir, 77
Insulin pump therapy, 78–79. See also Continuous subcutaneous insulin infusion
Insulin resistance
  development of, 9
  GDM and, 18
  obesity and, 12–13, 28
  pregnancy and, 17–18, 30
  type 1 diabetes and, 8–9
  in type 2 diabetes, 10, 28
  vitamin D and, 14
### Index 253

<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin signaling pathway</td>
<td>18</td>
</tr>
<tr>
<td>Insulin therapy</td>
<td>28</td>
</tr>
<tr>
<td>diabetes type and</td>
<td>29</td>
</tr>
<tr>
<td>hypoglycemia and</td>
<td>111–12, 112t</td>
</tr>
<tr>
<td>for type 1 diabetes</td>
<td>75–79</td>
</tr>
<tr>
<td>International Association of the Diabetes and Pregnancy Study Groups (IADPSG)</td>
<td>36</td>
</tr>
<tr>
<td>Intraoral conditions associated with diabetes</td>
<td>245</td>
</tr>
<tr>
<td>Invasive external otitis</td>
<td>48</td>
</tr>
<tr>
<td>Juvenile onset diabetes. See Type 1 diabetes</td>
<td></td>
</tr>
<tr>
<td>Ketoacidosis, type 2 diabetes and</td>
<td>9</td>
</tr>
<tr>
<td>Levemir insulin</td>
<td>215</td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>215</td>
</tr>
<tr>
<td>Lichen planus</td>
<td>174–75</td>
</tr>
<tr>
<td>Lifestyle change in</td>
<td>234</td>
</tr>
<tr>
<td>for type 2 diabetes</td>
<td>242</td>
</tr>
<tr>
<td>glycemic management of type 1 diabetes</td>
<td>73–74, 74f</td>
</tr>
<tr>
<td>and, 79–80</td>
<td></td>
</tr>
<tr>
<td>glycemic management of type 2 diabetes</td>
<td>79–80</td>
</tr>
<tr>
<td>and, 79–80</td>
<td></td>
</tr>
<tr>
<td>physical activity</td>
<td>73–74</td>
</tr>
<tr>
<td>for type 2 diabetes</td>
<td>242</td>
</tr>
<tr>
<td>sedentary, as risk factor</td>
<td>38</td>
</tr>
<tr>
<td>smoking</td>
<td></td>
</tr>
<tr>
<td>CHD and</td>
<td>57</td>
</tr>
<tr>
<td>periodontitis and</td>
<td>196</td>
</tr>
<tr>
<td>weight loss</td>
<td>39</td>
</tr>
<tr>
<td>Lipid dysregulation</td>
<td>132–33</td>
</tr>
<tr>
<td>Lipid-lowering agents</td>
<td>53</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>229</td>
</tr>
<tr>
<td>Liver infections</td>
<td>47–48</td>
</tr>
<tr>
<td>Macroalbuminuria</td>
<td>52</td>
</tr>
<tr>
<td>Macrovascular complications</td>
<td>55t</td>
</tr>
<tr>
<td>cerebrovascular disease</td>
<td>59</td>
</tr>
<tr>
<td>CHD, 55–59</td>
<td></td>
</tr>
<tr>
<td>PAD, 59–60</td>
<td></td>
</tr>
<tr>
<td>Macular edema</td>
<td>50–51</td>
</tr>
<tr>
<td>Masticatory function</td>
<td>245–46</td>
</tr>
<tr>
<td>Maturity onset diabetes of young (MODY)</td>
<td>3</td>
</tr>
<tr>
<td>classification of</td>
<td>30–31</td>
</tr>
<tr>
<td>diagnosis of</td>
<td>20</td>
</tr>
<tr>
<td>genetic mutations in</td>
<td>19–20</td>
</tr>
<tr>
<td>Medical complications of diabetes mellitus, 45–65. See also Oral complications of diabetes mellitus</td>
<td></td>
</tr>
<tr>
<td>acute</td>
<td></td>
</tr>
<tr>
<td>DKA, 45–46</td>
<td></td>
</tr>
<tr>
<td>HHS, 46</td>
<td></td>
</tr>
<tr>
<td>hypoglycemia, 46</td>
<td></td>
</tr>
<tr>
<td>infections, 46–49</td>
<td></td>
</tr>
<tr>
<td>chronic</td>
<td></td>
</tr>
<tr>
<td>macrovascular, 55–56</td>
<td></td>
</tr>
<tr>
<td>mechanisms of development, 49–50</td>
<td></td>
</tr>
<tr>
<td>microvascular, 50–55</td>
<td></td>
</tr>
<tr>
<td>51t</td>
<td></td>
</tr>
<tr>
<td>preventing, 64</td>
<td></td>
</tr>
<tr>
<td>Medical nutrition therapy (MNT), 73</td>
<td></td>
</tr>
<tr>
<td>Medications. See also specific medications</td>
<td></td>
</tr>
<tr>
<td>glucose levels and, 86–87</td>
<td></td>
</tr>
<tr>
<td>hypoglycemia-associated, 210, 211t</td>
<td></td>
</tr>
<tr>
<td>noninsulin, 84</td>
<td></td>
</tr>
<tr>
<td>oral diabetes, 113, 113t</td>
<td></td>
</tr>
<tr>
<td>for prevention, 39–40</td>
<td></td>
</tr>
<tr>
<td>side effects of</td>
<td>41</td>
</tr>
<tr>
<td>Meglitinides, for type 2 diabetes, 83</td>
<td></td>
</tr>
<tr>
<td>Mental illness</td>
<td>62</td>
</tr>
<tr>
<td>Metabolic control</td>
<td></td>
</tr>
<tr>
<td>dental caries and</td>
<td>159</td>
</tr>
<tr>
<td>periodontitis and</td>
<td>xiv</td>
</tr>
<tr>
<td>Metabolic goals for type 2 diabetes, 242t</td>
<td></td>
</tr>
<tr>
<td>Metabolic pathways, 133</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome, 234</td>
<td></td>
</tr>
<tr>
<td>diagnosis of</td>
<td>234t</td>
</tr>
<tr>
<td>Metabolism, PM inhalation and, 15</td>
<td></td>
</tr>
<tr>
<td>Metformin, 210, 234, 241</td>
<td></td>
</tr>
<tr>
<td>prevention and</td>
<td>39</td>
</tr>
<tr>
<td>side effects of</td>
<td>41</td>
</tr>
<tr>
<td>type 2 diabetes, 80</td>
<td></td>
</tr>
<tr>
<td>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), 48–49</td>
<td></td>
</tr>
<tr>
<td>Mexican Americans, prediabetes prevalence in, 31</td>
<td></td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>52</td>
</tr>
<tr>
<td>Microbiome</td>
<td></td>
</tr>
<tr>
<td>periodontal, 128</td>
<td></td>
</tr>
<tr>
<td>type 1 diabetes and</td>
<td>6–7</td>
</tr>
<tr>
<td>type 2 diabetes and</td>
<td>13–14</td>
</tr>
<tr>
<td>Microvascular complications</td>
<td>51t</td>
</tr>
<tr>
<td>diabetic foot, 54–55</td>
<td></td>
</tr>
<tr>
<td>nephropathy, 52–53</td>
<td></td>
</tr>
<tr>
<td>neuropathy, 53–54</td>
<td></td>
</tr>
<tr>
<td>retinopathy, 50–52</td>
<td></td>
</tr>
</tbody>
</table>
MNT. See Medical nutrition therapy
MODY. See Maturity onset diabetes of young
Mouse models, 28
MRSA. See Methicillin-resistant
Staphylococcus aureus
Musculoskeletal complications associated
with diabetes, 62

National Diabetes Data Group (NDDG), 36
National Health and Nutrition Examination
Survey (NHANES I), 144–45
National Institute of Diabetes, Digestive and
Kidney Diseases (NIDDK), 143–44
NDDG. See National Diabetes Data Group
Necrotizing fasciitis, 49
Nephropathy, 52–53
blood pressure control and, 53
drugs and, 53
periodontitis and, 144
Neuropathy
autonomic, 53–54
BMS and, 170–71
Neutral protamine hagedorn (NPH) insulin,
76–77
Neutrophils, periodontitis and, 128
NHANES I. See National Health and Nutrition
Examination Survey
NIDDK. See National Institute of Diabetes,
Digestive and Kidney Diseases
NIDDM. See Non-insulin dependent diabetes mellitus
Non-Hispanic blacks, prediabetes prevalence
in, 31
Non-Hispanic whites, prediabetes prevalence
in, 31
Non-insulin-dependent diabetes mellitus
(NIDDM), 27. See also Type 2
diabetes
Noninsulin medications, 84. See also specific
medications
Nonproliferative retinopathy (NPDR), 50–51
NPH insulin. See Neutral protamine hagedorn
insulin

Obesity
childhood, 29
diabetes and, 31, 32f
GDM and, 17
glucose dysregulation and, 134
insulin resistance and, 12–13, 28
periodontitis and, 134
as risk factor, 38
type 2 diabetes and, 12–13, 28, 134
Obstructive sleep apnea (OSA), 61
OGTT. See Oral glucose tolerance test
ONJ. See Osteonecrosis of the jaw
Oral bacteria, 152
Oral complications of diabetes mellitus, 144
access to dental services and, 181–82
BMS, 168–72
Candida infection, 163–68
dental caries, 157–60
dental implants, 175–81
mucosal lesions, 174–75
parotid sialosis/benign parotid hypertrophy,
172–74
xerostomia, 160–62
Oral diabetes medications, hypoglycemia
associated with, 113, 113t
Oral evaluation, 102
Oral glucose tolerance test (OGTT), 3
ACOG criteria, 37
Carpenter and Coustan plasma glucose
criteria, 36
for gestational diabetes, 36
NDDG criteria, 36
Oral health, 181–82
Oral surgery, case study of type 2 diabetes and,
209–14
Orlistat, 40
side effects of, 41
OSA. See Obstructive sleep apnea
Osteonecrosis of the jaw (ONJ), 63
PAD. See Peripheral arterial disease
Pain management in dental office, 117–18
Pancreas, 30–31
Pancreatic cancer, diabetes and, 20
Parotid sialosis/benign parotid hypertrophy,
172–74, 173f, 174f
chronic alcoholism and, 173–74
Particulate matter (PM), 15
PDR. See Proliferative retinopathy
Peri-implantitis, 235
Periodontal bacteria, 152
Periodontal bone loss, diabetes and, 131, 132f
Periodontal complications of diabetes, 144
Periodontal disease, xiii, 121–22
as complication of diabetes mellitus, 121–35
CVD and, 144
glycemic control and
longitudinal observational studies of, 143–45
treatment studies of, 145–50, 146t, 149t
underlying mechanisms of, 150–52, 151f
infections, 150–51
progression of, 126
type 2 diabetes and, 126, 144
Periodontal health
adverse effects of diabetes mellitus on, 122–27, 123t, 124t, 125t
biologic mechanisms contributing to, 127–32
children/adolescents with diabetes and, 126
GDM and, 126–27
glycemic control and, 124–26
type 1 diabetes and, 125–26
type 2 diabetes prediction and, 144–45
Periodontal Index, 145
Periodontal microbiome, 128
Periodontal microflora, 127–28
Periodontal re-evaluation, 110
Periodontal therapy, 109–10
anti-inflammatory effect of, 151–52
glycemic control and, 148, 149t
HbA1c changes after, 147, 150
long-term studies of, 100
for periodontitis, 99–100
results of, 99–101
type 2 diabetes and, 148
Periodontitis, 102
A. actinomyctemcomitans-induced, 131–32
chronic, 121
diabetes-enhanced, 129–30
diabetes mellitus and, xiii
diabetic complications and, 144
ESRD and, 144
metabolic control and, xiv
nephropathy and, 144
neutrophils and, 128
obesity and, 134
periodontal therapy for, 99–100
prevalence of, 122, 122f
progression of, 100
risk factors for, 196
type 2 diabetes and, 143
Peripheral arterial disease (PAD), 55, 59–60
Pharmacological therapy for type 2 diabetes, 81t
DPP-4 inhibitors, 83–84
GLP-1 receptor agonists, 83
α-glucosidase inhibitors, 84
insulin, 84–85
meglitinides, 83
metformin, 80
SGLT2, 84
sulfonylurea drugs, 83
thiazolidinediones, 84
Physical activity, 73–74
for type 2 diabetes, 242
Physician
dentist’s communication with, 104
diabetes management and, 203
glycemic control determination and, 107–8
questions for, 203–4
glycemic control level information from, 108
Pioglitazone, 39–40, 210
side effects of, 41
PKC. See Protein kinase C
PM. See Particulate matter
Polydipsia, 103, 111
Polyphagia, 103
Polyuria, 103, 111
Porphyromonas gingivalis, 129
Pramlintide therapy for type 1 diabetes, 79
Prandial insulin, 75
Prediabetes, 37
detecting, models for, 199, 200f
diagnosis of, 35
prevalence of, 31
screening for, 38
syndromes, vitamin D and, 14
Pregnancy. See also Gestational diabetes
insulin resistance and, 17–18, 30
type 2 diabetes developing after, 30
prevention for, 40, 41f
vitamin D in, 19
Prevention
bariatric surgery and, 40
do of diabetes, 21
Index

Prevention (cont’d)
of GDM, 40
of hypoglycemia, 114
medical complications of diabetes mellitus, 64
medications for, 39–40
side effects of, 41
of type 1 diabetes, 39
glycemic treatment and, 88
of type 2 diabetes, 39, 41
glycemic treatment and, 88–89
pregnancy and, 40, 41f
Probiotics, 7
Proliferative retinopathy (PDR), 50–51
Prosthodontic rehabilitation, case study of
  diabetes diagnosis after, 229–35,
  230f, 231f, 232f
Prosthodontic treatment, case study of type 2
  diabetes and, 237–46, 238f, 239f,
  240f, 244
Protein kinase C (PKC), 133–34
Pseudomonas aeruginosa, 48
PTPN22, 4

Race/ethnicity
diabetes and, 31
  risk factors and, 37–38
RAGE, 130–31
Random plasma glucose, 3, 33–34
Receptor activator of nuclear factor κB ligand
  osteoprotegerin ratio (RANKL:OPG), 129
Respiratory infections, 47
Retinopathy, 34, 50–52
  HbA1c and, 34–35, 34f
  NPDR, 50–51
  treatment of, 51
two-hour plasma glucose and, 34, 34f
Rhinocerebral mucormycosis, 48
Risk factors
dental, 102
environmental, 38
for GDM, 37–38
 genetic, 38
periodontitis, 196
racial/ethnic, 37–38
for type 1 diabetes, 37
for type 2 diabetes, 37–38, 191, 192t
Root caries, xiii, 157–58, 160f
Root planing, 110
Rosiglitazone, 39–40
side effects of, 41
Saliva, 160
diabetes and chemistry of, 162
inflammatory mediators in, 162
Salivary flow, 161–62
Salivary hypofunction, 160–61
Scaling, 110
Screening. See also specific screening tests
  medical models for diabetes, 191–92
  for prediabetes, 38
  for type 1 diabetes, 38
  for type 2 diabetes, 38–39, 192
Sedentary lifestyle, as risk factor, 38
Self-monitoring of blood glucose (SMBG), 70
Sexual dysfunction, 61–62
SGLT2. See Sodium-glucose cotransporter 2
Sick day management, 87
Single nucleotide polymorphisms (SNPs), 7
Skin and soft tissue infections, 48–49
Skin diseases associated with diabetes, 63, 64f
SMBG. See Self-monitoring of blood glucose
Smoking
  CHD and, 57
  periodontitis and, 196
SNPs. See Single nucleotide polymorphisms
Sodium-glucose cotransporter 2 (SGLT2), 84
SOS study. See Swedish Obese Subjects study
Staphylococcus aureus, 47
Stomatitis, 165, 165f
Streptococcus pneumoniae, 47
Subgingival microflora, altered, 127–28
Sulfonylurea drugs, 210
for type 2 diabetes, 83
Surgery
  bariatric, 40
  glycemic treatment and, 87–88
  oral, type 2 diabetes and, 209–13
  type 1 diabetes and, 88
  type 2 diabetes and, 88
Surgical site infections, 49
Susceptibility genes
  in type 1 diabetes, 4–5
  in type 2 diabetes, 10–11
Swedish Obese Subjects (SOS) study, 40
T1DGC. See Type 1 Diabetes Genetics Consortium
Tachycardia, 111
Tetracyclines, 110
Thiazolidinedione, 39
side effects, 41
Thiazolidinediones for type 2 diabetes, 84
TIA. See Transient ischemic attack
TNF-α dysregulation, 131
TNF-α inhibition, 131
Tooth loss
    progression of, 100
    type 2 diabetes and, 144
Transient ischemic attack (TIA), 59
Troglitazone, 39–40
Two-hour plasma glucose, 3
diabetes diagnosis and, 34
retinopathy and, 34, 34f
Type 1 diabetes
    autoimmunity and, 5–6
    β cell destruction and, 5, 28
classification of, 28
    contributory factors to development of, 9, 10f
dental care case study for, 205–8
dental caries and, 159
diabetes management in dental office and, 105–6
DKA in, 45
genetics of, 4–5, 5t
glycemic management of
    home glucose monitoring and, 75
    insulin therapy for, 75–79
    lifestyle and, 73–74, 74f
    pramlintide therapy for, 79
GWAS in, 4–5
HbA1c values and, 108–9
host inflammatory response and, 128–29
hypoglycemia unawareness, 114
incidence of, 29f
infectious agents and, 6
insulin deficiency of, 28
insulin resistance and, 8–9
microbiome and, 6–7
non-HLA loci associated with, 4–5, 5t
pathogenesis of, 3, 5–8
periodontal health and, 125–26
prevention of, 39
glycemic treatment and, 88
rise of, 21
risk factors for, 37
screening for, 38
surgery and, 88
susceptibility genes in, 4–5
type 2 distinguished from, 29–30
vitamin D and, 7–8
Type 1 Diabetes Genetics Consortium (T1DGC), 4
Type 2 diabetes, 9–16, 41–42
    age and, 9
    β cell function in, 10, 28
classification of, 28
    contributory factors to development of, 16, 16f
dental caries and, 158–59
diabetes management in dental office and, 105–6
DKA in, 45
environmental pollution and, 15
GDM and, 9–10
genetics of, 10–11, 12t, 15–16
glycemic management of
    lifestyle and, 79–80
    pharmacological therapy for, 80–85
GWAS in, 11
HbA1c values and, 108–9
HHS in, 46
host inflammatory response and, 128–29
hypoglycemia unawareness, 114
incidence of, 29f
insulin and, 30, 84–85
insulin resistance in, 10, 28
lifestyle changes for, 242
loci associated with, 11, 12t
metabolic goals for, 242t
microbiome and, 13–14
obesity and, 12–13, 28, 134
oral surgery and, case study of, 209–14
pathogenesis of, 3, 11–15
periodontal disease and, 126, 144
periodontal health and predicting, 144–45
periodontal therapy and, 148
periodontitis and, 143
pharmacological therapy for, 80–85, 81t
post-pregnancy development of, 30
    preventing, 40, 41f
prevalence of, 9
Type 2 diabetes (cont’d)
prevention of, 39, 41
glycemic treatment and, 88–89
pregnancy and, 40, 41f
prosthodontic treatment and, case study of, 237–46
rise of, 21
risk factors for, 37–38, 191, 192t
screening for, 38–39, 192
surgery and, 88
oral, 209–14
susceptibility genes in, 10–11
testing for, 241
tooth loss and, 144
treatment of, 241
type 1 distinguished from, 29–30
vitamin D and, 14–15

Uncoupling of bone resorption and bone formation, 131–32

Undiagnosed diabetes
dental office evaluation and management of, 101–4, 103f
identification of dental patients with, 191–200, 195t
diabetes testing in dental settings and, 196–99
medical history and, 102
medical models for diabetes screening, 191–92
signs and symptoms of, 102

VDR. See Vitamin D receptor

Vitamin D
GDM and, 18–19
insulin resistance and, 14
levels of, 14
prediabetes syndromes and, 14
in pregnancy, 19
supplementation, 8, 14
type 1 diabetes and, 7–8
type 2 diabetes and, 14–15

Weight loss, 39
Wound healing, impaired, 132–33

Xerostomia, xiii, 160–62
candidiasis and, 226
dental caries and, 226
diabetes and, case study of, 221–26, 222f, 223f